These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 30275538)

  • 41. Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of activating NK receptor.
    Inoue T; Adachi K; Kawana K; Taguchi A; Nagamatsu T; Fujimoto A; Tomio K; Yamashita A; Eguchi S; Nishida H; Nakamura H; Sato M; Yoshida M; Arimoto T; Wada-Hiraike O; Oda K; Osuga Y; Fujii T
    Int J Oncol; 2016 Oct; 49(4):1297-304. PubMed ID: 27499237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
    Chiang EY; Mellman I
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acetate decreases PVR/CD155 expression via PI3K/AKT pathway in cancer cells.
    Tran NL; Lee IK; Choi J; Kim SH; Oh SJ
    BMB Rep; 2021 Aug; 54(8):431-436. PubMed ID: 34353426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Contribution of inhibitory receptor TIGIT to NK cell education.
    He Y; Peng H; Sun R; Wei H; Ljunggren HG; Yokoyama WM; Tian Z
    J Autoimmun; 2017 Jul; 81():1-12. PubMed ID: 28438433
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
    Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT.
    Matsuo T; Iguchi-Manaka A; Shibuya A; Shibuya K
    Cancer Sci; 2022 Nov; 113(11):4001-4004. PubMed ID: 35947095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors.
    Yang F; Zhang F; Ji F; Chen J; Li J; Chen Z; Hu Z; Guo Z
    Front Immunol; 2023; 14():1175920. PubMed ID: 37359558
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blocking TIGIT/CD155 signalling reverses CD8
    Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
    J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Platform for Extracellular Interactome Discovery Identifies Novel Functional Binding Partners for the Immune Receptors B7-H3/CD276 and PVR/CD155.
    Husain B; Ramani SR; Chiang E; Lehoux I; Paduchuri S; Arena TA; Patel A; Wilson B; Chan P; Franke Y; Wong AW; Lill JR; Turley SJ; Gonzalez LC; Grogan JL; Martinez-Martin N
    Mol Cell Proteomics; 2019 Nov; 18(11):2310-2323. PubMed ID: 31308249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aberrant expression of junctional adhesion molecule-A contributes to the malignancy of cervical adenocarcinoma by interaction with poliovirus receptor/CD155.
    Murakami T; Takasawa A; Takasawa K; Akimoto T; Aoyama T; Magara K; Saito Y; Ota M; Kyuno D; Yamamoto S; Hasegawa T; Saito T; Osanai M
    Cancer Sci; 2021 Feb; 112(2):906-917. PubMed ID: 33185939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer.
    Jiang C; Qu X; Ma L; Yi L; Cheng X; Gao X; Wang J; Che N; Zhang H; Zhang S
    Clin Exp Immunol; 2022 Jun; 208(2):220-232. PubMed ID: 35262683
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of poliovirus receptor, CD155 expression in different human colorectal cancer cell lines: Implications for poliovirus virotherapy.
    Zhand S; Hosseini SM; Tabarraei A; Moradi A; Saeidi M
    J Cancer Res Ther; 2019; 15(1):61-67. PubMed ID: 30880756
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD155/TIGIT signaling regulates the effector function of tumor-infiltrating CD8+ T cell by NF-κB pathway in colorectal cancer.
    Li S; Ding J; Wang Y; Wang X; Lv L
    J Gastroenterol Hepatol; 2022 Jan; 37(1):154-163. PubMed ID: 34734434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nectin-like interactions between poliovirus and its receptor trigger conformational changes associated with cell entry.
    Strauss M; Filman DJ; Belnap DM; Cheng N; Noel RT; Hogle JM
    J Virol; 2015 Apr; 89(8):4143-57. PubMed ID: 25631086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
    Shibuya A; Shibuya K
    Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155).
    Fuchs A; Cella M; Giurisato E; Shaw AS; Colonna M
    J Immunol; 2004 Apr; 172(7):3994-8. PubMed ID: 15034010
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance.
    Zhang H; Zhang Y; Dong J; Li B; Xu C; Wei M; Wu J; Wei J
    Mol Ther Oncolytics; 2021 Mar; 20():12-22. PubMed ID: 33575467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization and identification of Tage4 as the murine orthologue of human poliovirus receptor/CD155.
    Ravens I; Seth S; Förster R; Bernhardt G
    Biochem Biophys Res Commun; 2003 Dec; 312(4):1364-71. PubMed ID: 14652024
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CD155 is a putative therapeutic target in medulloblastoma.
    Li S; McLendon R; Sankey E; Kornahrens R; Lyne AM; Cavalli FMG; McKay Z; Herndon JE; Remke M; Picard D; Gromeier M; Brown M; Thompson EM
    Clin Transl Oncol; 2023 Mar; 25(3):696-705. PubMed ID: 36301489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.